Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy [0.03%]
布ем佐治疗二线及以上难治慢性移植物抗宿主病的西班牙真实世界经验
Rebeca Bailén,Felipe Peña-Muñoz,Arancha Bermúdez et al.
Rebeca Bailén et al.
Background: . Belumosudil was approved by the FDA for the treatment of chronic graft-versus-host disease (cGVHD) after at least two prior lines of therapy. ...
Ruxolitinib as a Steroid-Sparing Treatment for Chronic Graft vs Host Disease [0.03%]
鲁索利替尼作为慢性移植物抗宿主病的糖皮质激素减量药物治疗
Eleanor Cook,Nicholas Gloude,Alan Bidgoli et al.
Eleanor Cook et al.
Impact of Intensive Cyclophosphamide-containing multi-agent Bridging Therapy on Outcomes After Idecabtagene Vicleucel in Multiple Myeloma [0.03%]
高强度环磷酰胺为基础的联合桥接治疗在倍利兹治疗多发性骨髓瘤中的疗效和安全性：一项单中心研究
Taku Kikuchi,Ukyo Kondo,Shotaro Sugita et al.
Taku Kikuchi et al.
Background: Bridging therapy (BT) is frequently required during manufacturing of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy in relapsed/refractory multiple myeloma. In patie...
Impact of donor characteristics on the outcomes following haplo-HSCT in patients aged 55 years and older [0.03%]
供者特征对大于55岁接受单倍型相合造血干细胞移植患者预后影响分析
Wei Zhao,Rui Ma,Xueyi Luo et al.
Wei Zhao et al.
Background: Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) provides curative potential for older patients with haematological malignancies. Since multiple haploidentical donors may be available for a...
Kidney and blood pressure outcomes in children surviving at least 6 months after hematopoietic stem cell transplant: a systematic review and meta-analysis [0.03%]
造血干细胞移植后存活至少六个月的儿童肾脏及血压状况系统评价和序贯性分析
Carolyn Sun,Sahrish Masood,Jenan-Jill Kiyingi et al.
Carolyn Sun et al.
Pediatric hematopoietic stem cell transplant (HSCT) recipients are at risk for developing kidney and high blood pressure (BP) conditions, however their prevalence is unclear. We aimed to evaluate 1) the proportion of patients with late kidn...
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma [0.03%]
CD19嵌合抗原受体T细胞治疗大B细胞淋巴瘤长期疗效的标志物评估研究
Marina Gomez-Llobell,Roni Shouval,Samantha Brown et al.
Marina Gomez-Llobell et al.
CAR T-cell therapy has transformed relapsed/refractory large B-cell lymphoma (LBCL) treatment, yet durable remissions remain challenging. In this retrospective multicenter study, 479 LBCL patients treated with commercial CD19 CAR-T products...
Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies [0.03%]
儿童和年轻成人血液系统恶性肿瘤患者HLA配型相合造血干细胞移植后使用米托蒽醌诱导缓解联合环磷酰胺预处理的临床研究
Megan Murphy,Hua-Ling Tsai,Allen Chen et al.
Megan Murphy et al.
Background: High-dose posttransplant cyclophosphamide (PTCy) for graft versus host disease (GVHD) prophylaxis after HLA-matched allogeneic hematopoietic cell transplantation (HCT) in adults with hematologic malignancies i...
Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights from a US Multicenter Transplant and Cellular Therapy Network [0.03%]
急性淋巴细胞 leukemia CART治疗的门诊与住院模式：一项美国多中心移植和细胞治疗网络的研究见解
Minoo Battiwalla,Shanna Arnold Egloff,Gita Nadimpalli et al.
Minoo Battiwalla et al.
Background: Axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved for treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Due to risks of cytokine ...
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles [0.03%]
实体瘤的细胞治疗进展：克服生物、运营和监管障碍的途径
Kedar Kirtane,Michael Kalos,Rocky Billups et al.
Kedar Kirtane et al.
Cellular therapies have revolutionized the treatment of hematologic malignancies and are now emerging as potentially promising interventions for solid tumors. While considerable learnings can be leveraged from hematologic applications to in...
Francisco Barriga
Francisco Barriga